Accessibility Menu
Cardiff Oncology logo

Cardiff Oncology(NASDAQ) CRDF

Market Cap$65.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-100%
5 Year-85%
1 Year-76%
1 Month-36%
$0.86
+5.95%
+0.05Today
Cardiff Oncology last closing stock price
MetricPriceDate
Last closeUSD 0.812026-07-29
Cardiff Oncology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.81%USD 0.862026-07-22
1 month-36.22%USD 1.272026-06-29
3 month-53.18%USD 1.732026-04-30
Year to date-71.17%USD 2.812025-12-31
1 year-75.53%USD 3.312025-07-29
3 year-49.38%USD 1.602023-07-28
5 year-84.77%USD 5.322021-07-30
Since inception-99.95%USD 1,620.002004-07-27

Cardiff Oncology Financials at a Glance

Market Cap

$65.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$525.00K

Net Income (TTM)

-$44.76M

EPS (TTM)

-$0.67

P/E Ratio

-1.28

Dividend

$0.00

Beta (Volatility)

1.73 (High)

Price

$0.86

Volume

1,385,715.612

Open

$0.79

Previous Close

$0.85

Daily Range

$0.78 - $0.87

52-Week Range

$0.76 - $3.31

Estimated Earnings Date

Aug 4, 2026

CRDF News

Foolcom-Featured.png

Cardiff Oncology (CRDF) Q2 Loss Down 19%

Motley Fool Markets TeamJul 30, 2025
trader analyzing data

These 2 Nasdaq Stocks Are Poised to Make Big Moves Today

George Budwell, PhDJan 19, 2022
cancer cells

1 Cancer Stock on Buyout Watch in 2022

George Budwell, PhDNov 21, 2021
cardiff

Why Cardiff Oncology Shares Were Up More Than 15% on Thursday

James HalleyNov 18, 2021
biotech

Why Shares of Cardiff Oncology Rose on Monday

James HalleySep 13, 2021
Why_Cardiff_Oncology_Ran_Up_1,350__in_2020

Why Cardiff Oncology Ran Up 1,350% in 2020

Taylor CarmichaelJan 31, 2021
Red line pointing down

Why Cardiff Oncology Stock Is Crashing Today

Keith SpeightsJan 15, 2021
rolled-up-dollar-bills-stacked-next-to-each-other-indicating-growth

2 Biotech Stocks That Keep on Climbing

Cory RenauerOct 15, 2020
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cardiff Oncology

Cardiff Oncology, Inc. is a biotechnology firm focusing on developing innovative cancer therapies. The company aims to meet significant medical needs through its proprietary drug platform and biomarker-driven trials, enhancing treatment efficacy and specificity.

Products and Services

Lead candidate for precision cancer treatment

What Makes Cardiff Oncology, Inc. Special

Cardiff Oncology distinguishes itself by conducting biomarker-driven trials, ensuring higher efficacy and specificity in its cancer treatments. Its leadership team, with extensive industry experience, provides strategic direction and expertise.

Five Things You Need to Know

Focuses on precision medicine to address unmet medical needs in oncology.

Utilizes a proprietary drug development platform for its therapies.

Conducts biomarker-driven clinical trials to enhance treatment effectiveness.

Leverages partnerships with research institutions and pharmaceutical companies.

Aims to expand clinical indications and market potential for its lead drug candidate.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

31

CEO

Mani Mohindru, PhD

Website

www.cardiffoncology.com

Headquarters

San Diego, CA 92121, US

CRDF Financials

Key Financial Metrics (TTM)

Gross Margin

-2105.71%

Operating Margin

-9033.90%

Net Income Margin

-8526.10%

Return on Equity

-95.50%

Return on Capital

-105.93%

Return on Assets

-91.03%

Earnings Yield

-78.13%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$65.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

77.07M

Volume

1.39M

Avg. Volume

1.55M

Financials (TTM)

Gross Profit

-$11.06M

Operating Income

-$47.43M

EBITDA

-$43.73M

Operating Cash Flow

-$37.42M

Capital Expenditure

-$44.00K

Free Cash Flow

-$37.46M

Cash & ST Invst.

$46.06M

Total Debt

$646.00K

Cardiff Oncology Performance Analysis

Cardiff Oncology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 386,0007.5%
20232023-12-31USD 488,00026.4%
20242024-12-31USD 683,00040.0%
20252025-12-31USD 593,000-13.2%
Cardiff Oncology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3011.0%
Q32025-09-30-0.8%
Q42025-12-31102.5%
Q12026-03-31-83.1%
Cardiff Oncology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.8922.4%
20232023-12-31USD -0.934.5%
20242024-12-31USD -0.952.8%
20252025-12-31USD -0.69-28.0%
Cardiff Oncology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3025.0%
Q32025-09-3019.0%
Q42025-12-3135.3%
Q12026-03-31-63.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$41.00K

-62.4%

Gross Profit

$41.00K

-62.4%

Gross Margin

100.00%

N/A

Market Cap

$65.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.12M

N/A

Employees

31

N/A

Net Income

-$12.35M

+8.1%

EBITDA

-$12.12M

+8.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$46.06M

-42.3%

Total Debt

$646.00K

-52.4%

Accounts Receivable

$191.00K

-52.8%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$646.00K

-9.8%

Return on Assets

-91.03%

N/A

Return on Invested Capital

-1.37%

N/A

Free Cash Flow

-$12.29M

+4.0%

Operating Cash Flow

-$12.29M

+4.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SAVACassava Sciences, Inc.
$1.32+2.33%
ELTXElicio Therapeutics, Inc.
$2.91+0.69%
RANIRani Therapeutics Holdings, Inc.
$0.82-2.80%
MISTMilestone Pharmaceuticals Inc.
$1.15+10.58%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.13+0.11%
NVDANvidia
$195.04+0.03%
MSFTMicrosoft
$451.10+0.16%
NOKNokia
$9.09+0.08%

Questions About CRDF

What is the current price of Cardiff Oncology?

Cardiff Oncology is trading at $0.85 per share.

What is the 52-week range for Cardiff Oncology?

Over the past 52 weeks, Cardiff Oncology has traded between $0.76 and $3.31.

How much debt does Cardiff Oncology have?

As of the most recent reporting period, Cardiff Oncology reported total debt of $646.00K.

How much cash does Cardiff Oncology have on hand?

Cardiff Oncology reported $8.54M in cash and cash equivalents in its most recent financial results.

What is Cardiff Oncology’s dividend yield?

Cardiff Oncology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services